J&J's Er­lea­da/Zyti­ga com­bo hits PhI­II end­point — but what about OS?; Tar­go­v­ax los­es prostate can­cer part­ner af­ter en­roll­ment strug­gles

J&J says a com­bi­na­tion of Er­lea­da and Zyti­ga, two of its big prostate can­cer drugs, has met the pri­ma­ry end­point of ra­di­ograph­ic pro­gres­sion-free sur­vival in a Phase III study — but fell short of help­ing pa­tients live longer.

Specif­i­cal­ly, the ACIS study re­cruit­ed pa­tients with chemother­a­py-naïve metasta­t­ic cas­tra­tion-re­sis­tant prostate can­cer re­ceiv­ing an­dro­gen de­pri­va­tion ther­a­py. In­ves­ti­ga­tors found that adding Er­lea­da to a reg­i­men of Zyti­ga plus pred­nisone ex­tend­ed me­di­an rPFS by 6 months (22.6 ver­sus 16.6 months).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER